Earnings summaries and quarterly performance for Vertex.
Executive leadership at Vertex.
Board of directors at Vertex.
AW
Amanda Westphal Radcliffe
Detailed
Director
BG
Bradley Gayton
Detailed
Director
DD
David DeStefano
Detailed
Chairperson of the Board
EA
Eric Andersen
Detailed
Lead Independent Director
JR
J. Richard Stamm
Detailed
Director
MJ
Mark J. Mendola
Detailed
Director
PS
Philip Saunders
Detailed
Director
SW
Stefanie Westphal Thompson
Detailed
Director
Research analysts who have asked questions during Vertex earnings calls.
Adam Hotchkiss
Goldman Sachs
4 questions for VERX
Also covers: ALKT, ALRM, BL +12 more
Christopher Quintero
Morgan Stanley
4 questions for VERX
Also covers: BILL, BL, BOX +7 more
JR
Joshua Reilly
Needham & Company
4 questions for VERX
Also covers: AEYE, ASUR, AUDC +15 more
Robert Oliver
Robert W. Baird & Co.
4 questions for VERX
Also covers: AMPL, ASAN, AZPN +17 more
AS
Alexander Sklar
Raymond James Financial, Inc.
3 questions for VERX
Also covers: AIOT, BL, DUOL +11 more
DJ
Daniel Jester
BMO Capital Markets
3 questions for VERX
Also covers: ADP, BL, DAY +11 more
Jacob Roberge
William Blair
3 questions for VERX
Also covers: APPN, BL, DDOG +14 more
PW
Patrick Walravens
Citizens JMP
3 questions for VERX
Also covers: AI, ALKT, ASAN +26 more
SE
Steven Enders
Citigroup Inc.
3 questions for VERX
Also covers: APPN, ASAN, BL +14 more
AD
Andrew DeGasperi
BNP Paribas
2 questions for VERX
Also covers: DDOG, IOT, NAVN +4 more
SS
Samad Samana
Jefferies
2 questions for VERX
Also covers: ADP, ALRM, AUDC +19 more
WJ
Will Jellison
D.A. Davidson & Co.
2 questions for VERX
Also covers: ADSE, BL, MANH +3 more
AS
Alex Sklar
Raymond James & Associates, Inc.
1 question for VERX
Also covers: INTA, IOT, KARO +2 more
BR
Brad Reback
Stifel
1 question for VERX
Also covers: ASUR, CFLT, DAY +10 more
Brent Bracelin
Piper Sandler Companies
1 question for VERX
Also covers: ADBE, AMPL, ASAN +20 more
George Kurosawa
Citigroup Inc.
1 question for VERX
Also covers: BOX, INTA, MANH +5 more
JR
Jake Roberge
William Blair & Company, L.L.C
1 question for VERX
Also covers: ADBE, APPN, ARCT +13 more
MS
Matthew Stotler
William Blair & Company
1 question for VERX
Also covers: GDYN
NH
Natalie Howe
Bank of America
1 question for VERX
Also covers: BIGC, ENFN, INTA
PW
Pat Walravens
Citizens JMP Securities, LLC
1 question for VERX
Also covers: ALKT, BL, DOMO +2 more
Recent press releases and 8-K filings for VERX.
Teva and Royalty Pharma Enter Funding Agreement for TEV-‘408 Development
VERX
New Projects/Investments
- Teva Pharmaceuticals and Royalty Pharma have entered a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408.
- This funding includes $75 million from Royalty Pharma for a Phase 2b study of TEV-‘408 in vitiligo, which is targeted to begin in 2026.
- Royalty Pharma also has an option to provide an additional $425 million to co-fund Phase 3 development, contingent on future Phase 2b results.
- TEV-‘408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, with trial results anticipated during 2026.
Jan 11, 2026, 10:00 PM
Entrada Therapeutics Updates on Clinical Pipeline Progress and Cash Runway
VERX
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates reporting data from the first cohort of ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, both for Duchenne muscular dystrophy.
- The company plans to initiate a global Phase 1/2 clinical study for ENTR-601-50 by the end of 2026 and submit global regulatory applications for ENTR-601-51 in 2026.
- Entrada has expanded its pipeline into ocular diseases, selecting ENTR-801 as its first clinical candidate for Usher syndrome type 2A and expecting to nominate a second ocular clinical candidate in 2026.
- Entrada Therapeutics projects a cash runway into Q3 2027.
Jan 8, 2026, 12:00 PM
Septerna Reports Third Quarter 2025 Financial Results and Provides Business Updates
VERX
Earnings
Guidance Update
New Projects/Investments
- Septerna reported revenue of $21.5 million and net income of $8.2 million for the third quarter ended September 30, 2025.
- The company's cash, cash equivalents, and marketable securities totaled $561.6 million as of September 30, 2025, which is expected to support operations at least into 2029.
- Key pipeline advancements include the selection of SEP-479 as a development candidate with a Phase 1 trial planned for initiation in the first half of 2026, and an ongoing Phase 1 clinical trial for SEP-631 with initial data expected in the first half of 2026.
- Septerna's global collaboration and license agreement with Novo Nordisk formally commenced in July, and Keith Gottesdiener, M.D., was appointed to its Board of Directors in September.
Nov 10, 2025, 12:00 PM
Vertex Presents Updated Povetacicept Clinical Data and Regulatory Milestones
VERX
New Projects/Investments
Product Launch
- Vertex Pharmaceuticals presented updated Phase 1/2 RUBY-3 study data for povetacicept in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) at ASN Kidney Week 2025.
- In IgAN, 48-week data showed a 64% decrease from baseline in proteinuria and eGFR stabilization; in pMN, data showed an 82% decrease from baseline in proteinuria and eGFR stabilization.
- Povetacicept was generally safe and well tolerated with mostly mild or moderate adverse events and no serious adverse events related to the drug.
- Vertex is on track to initiate a rolling Biologics License Application (BLA) submission this year for potential accelerated approval of povetacicept in IgAN, which has received Breakthrough Therapy Designation.
- The Phase 3 RAINIER trial for IgAN is fully enrolled, and the Phase 2/3 OLYMPUS trial for pMN, which received Fast Track Designation, is underway.
Nov 8, 2025, 10:15 PM
Vertex Reports Third Quarter 2025 Financial Results
VERX
Earnings
Guidance Update
New Projects/Investments
- Vertex reported total revenue of $3.08 billion for the third quarter ended September 30, 2025, an 11% increase compared to the third quarter of 2024.
- The company refined its full year 2025 financial guidance, with total revenue now expected to be $11.9 to $12.0 billion and combined non-GAAP R&D, AIPR&D, and SG&A expenses projected at $5.0 to $5.1 billion.
- GAAP net income for Q3 2025 was $1.1 billion, and non-GAAP net income was $1.2 billion.
- As of September 30, 2025, cash, cash equivalents, and total marketable securities stood at $12.0 billion.
- Vertex advanced its R&D pipeline, completing full enrollment for the povetacicept Phase 3 IgAN trial and the interim analysis cohort for the AMPLITUDE Phase 2/3 trial of inaxaplin, and is on track to submit the first module of the povetacicept IgAN BLA to the FDA by the end of 2025.
Nov 3, 2025, 9:02 PM
Vertex (VERX) Reports Q3 2025 Results, Announces CEO Succession, and Share Buyback
VERX
Earnings
CEO Change
Share Buyback
- Vertex (VERX) reported Q3 2025 revenue of $192.1 million, up 12.7% year-over-year, driven by 29.6% cloud revenue growth and a record $43.5 million in adjusted EBITDA.
- Net Revenue Retention (NRR) decreased to 107%, impacted by approximately $2 million from three large customer bankruptcies and over $2 million from accelerated cloud platform migrations.
- The company announced a CEO succession plan, with Chris Young appointed as the new CEO, and authorized a $150 million share repurchase program.
- For full-year 2025, Vertex (VERX) updated its revenue guidance to $745.7 million-$749.7 million and adjusted EBITDA guidance to $159 million-$161 million.
Nov 3, 2025, 1:30 PM
Vertex Reports Strong Q3 2025 Revenue Growth
VERX
Earnings
Revenue Acceleration/Inflection
- Vertex Inc. reported Q3 2025 revenues of $192.11 million, an increase of 12.7% year-over-year, driven by strong demand for its cloud-based tax compliance solutions.
- The company's adjusted earnings per share were $0.17, surpassing analyst estimates of $0.16, despite a decrease in net profit to $4.04 million compared to the prior year.
- Cloud revenues grew by 29.6% year-over-year, reflecting a significant migration to cloud-based systems for indirect tax compliance.
Nov 3, 2025, 12:20 PM
Vertex Announces Q3 2025 Financial Results, Stock Repurchase Program, and CEO Transition
VERX
Earnings
Share Buyback
CEO Change
- Vertex reported Q3 2025 total revenues of $192.1 million, a 12.7% year-over-year increase, with cloud revenues growing 29.6% to $92.0 million. Non-GAAP diluted EPS for the quarter was $0.17.
- The Board authorized a new stock repurchase program of up to $150 million of Class A common stock, effective October 30, 2025, marking the company's first such program.
- The company issued Q4 2025 revenue guidance of $192.0 million to $196.0 million and full-year 2025 revenue guidance of $745.7 million to $749.7 million, with full-year cloud revenue growth expected at 28%.
- David DeStefano will transition to non-executive chairperson, and Christopher Young will join as President and CEO later in November 2025.
Nov 3, 2025, 12:20 PM
Vertex Announces Q3 2025 Financial Results, $150 Million Stock Repurchase Program, and CEO Transition
VERX
Earnings
Share Buyback
CEO Change
- Vertex reported third quarter 2025 financial results on November 3, 2025, with total revenues of $192.1 million, an increase of 12.7% year-over-year, and cloud revenues growing 29.6% year-over-year to $92.0 million. The company also achieved Non-GAAP diluted EPS of $0.17 and Adjusted EBITDA of $43.5 million for the quarter.
- The company issued financial guidance for Q4 2025, expecting revenues between $192.0 million and $196.0 million and Adjusted EBITDA between $40.0 million and $42.0 million. For the full-year 2025, Vertex anticipates revenues of $745.7 million to $749.7 million and Adjusted EBITDA of $159.1 million to $161.1 million.
- Vertex's Board of Directors authorized a $150 million stock repurchase program for its Class A common stock on October 30, 2025.
- David DeStefano will transition to non-executive chairperson of the Board, and Christopher Young is set to join Vertex as President and CEO later in November 2025.
Nov 3, 2025, 12:05 PM
Calix Launches Next-Generation AI-Powered Broadband Platform
VERX
Product Launch
New Projects/Investments
- Calix announced the new generation of its Calix Broadband Platform, developed for "agentic" AI and built on Google Cloud's AI and data infrastructure, including Vertex AI and Gemini models.
- This platform is designed to simplify operations, accelerate innovation, and drive value for broadband service providers (BSPs).
- Calix has invested over $100 million since November 2023 to strategically evolve its broadband platform towards "agentic" AI.
- The next-generation platform is scheduled to be available later this quarter.
Oct 22, 2025, 6:11 PM
Quarterly earnings call transcripts for Vertex.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more